EDINBURGH, Scotland, Jan. 17, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announces a strategic collaboration with The University of Texas MD Anderson Cancer Center to expand the knowledge base of how gamma-delta T cells work in oncology settings.
Read more at prnewswire.comTC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
/Accenture%20plc%20buiding%20with%20logo-by%20JHVEPhoto%20via%20iStock.jpg)